Department of Internal Medicine (JPM, SKA), San Antonio Military Medical Center, San Antonio, Texas; College of Pharmacy (CRF, KRD), The University of Texas at Austin, Austin, Texas; Pharmacotherapy Education and Research Center (CRF, KRD), School of Medicine, University of Texas Health Science Center, San Antonio, Texas; VA North Texas Health Care System (EMM); University of Texas Southwestern Medical Center (EMM), Dallas, Texas; South Texas Veterans Health Care System (MJP); Department of Epidemiology and Biostatistics (MJP), University of Texas Health Science Center, San Antonio, Texas; Division of Pharmaceutical Outcomes and Policy (CUO), UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina; Brooke Army Medical Center (IAM); and Uniformed Service University of Health Sciences (IAM); University of Texas Health Science Center, San Antonio, Texas (IAM).
Am J Med Sci. 2014 Mar;347(3):211-6. doi: 10.1097/MAJ.0b013e31828318e2.
Statins have been postulated to prevent infection through immunomodulatory effects.
To compare the incidence of infections in statin users to that in nonusers within the same health care system.
This was a retrospective cohort study of patients enrolled as Tricare Prime or Plus in the San Antonio military multimarket. Statin users were patients who received a statin for at least 3 months between October 1, 2004 and September 30, 2005. Nonusers were patients who did not receive a statin within the study period (October 1, 2003-September 30, 2009). Inpatient and outpatient International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes were used to determine the incidence of infections during the follow-up period (October 1, 2005-September 30, 2009) via multivariable regression analysis and time to infection via Cox regression analysis.
Of 45,247 patients who met the study criteria, 12,981 (29%) were statin users and 32,266 were nonusers. After adjustments for age, gender, Charlson Comorbidity Score, tobacco use, alcohol abuse/dependence, health care utilization and use of specific medication classes, statin use was associated with an increased incidence of common infections (odds ratio [OR]: 1.13; 95% confidence interval [CI]: 1.06-1.19) but not influenza or fungal infections (OR: 1.06, 95% CI: 0.80-1.39; OR: 0.97; 95% CI: 0.91-1.04, respectively). Time-to-first infection was similar in statin users and nonusers in all infection categories examined.
Statin use was associated with an increased incidence of common infections but not influenza or fungal infections. This study does not support a protective role of statins in infection prevention; however, the influence of potential confounders cannot be excluded.
他汀类药物被认为通过免疫调节作用来预防感染。
在同一医疗体系内比较他汀类药物使用者和非使用者的感染发生率。
这是一项回顾性队列研究,研究对象为在圣安东尼奥军事多市场参加 Tricare Prime 或 Tricare Plus 的患者。他汀类药物使用者是指在 2004 年 10 月 1 日至 2005 年 9 月 30 日期间至少接受 3 个月他汀类药物治疗的患者。非使用者是指在研究期间(2003 年 10 月 1 日至 2009 年 9 月 30 日)未接受他汀类药物治疗的患者。通过多变量回归分析和感染时间的 Cox 回归分析,使用住院和门诊国际疾病分类,第 9 修订版,临床修正(ICD-9-CM)代码确定随访期间(2005 年 10 月 1 日至 2009 年 9 月 30 日)感染的发生率。
在符合研究标准的 45247 名患者中,有 12981 名(29%)为他汀类药物使用者,32266 名患者为非使用者。在校正年龄、性别、Charlson 合并症评分、吸烟、酗酒/依赖、医疗保健利用和特定药物类别使用后,他汀类药物使用与常见感染发生率增加相关(比值比 [OR]:1.13;95%置信区间 [CI]:1.06-1.19),但与流感或真菌感染无关(OR:1.06,95% CI:0.80-1.39;OR:0.97;95% CI:0.91-1.04)。在所有检查的感染类别中,他汀类药物使用者和非使用者的首次感染时间相似。
他汀类药物使用与常见感染发生率增加相关,但与流感或真菌感染无关。本研究不支持他汀类药物在预防感染方面具有保护作用;然而,不能排除潜在混杂因素的影响。